DOI: 10.36347/sjams.2018.v06i02.018

Pages: 548-552

ESBL (extended spectrum beta lactamase) producing enterobactericeae are resistant to betalactam group of antibiotics causing a great threat to their treatment options .The present study was undertaken to determine in-vitro sensitivity of some betalactam/ betalactamase combinations like cefipime, cefpirome, ceftazidime, ceftriaxone with sulbactam along with Tobracef (Tobramycin+Ceftazidime) against these group of enterobacteriaceae in order to choose an alternative treatment options. A total of 505 clinical samples were tested. 168 gram negative bacilli were isolated from those samples. Those isolates were screened for ESBL production by methods recommended of CLSI. Maximum ESBL production was seen amongst E.coli & Klebsiella species. Susceptibility pattern of different Cephalosporin with beta lactamase inhibitor combinations were tested amongst these ESBL strains. Showed E.coli & Klebsiella showed highest sensitivity to Supime disc (cefipime + sulbactam), Pseudomonas to Supime (cefipime + sulbactam), Zydotum (Ceftazidime + sulbactum), Acinetobacter to Pirotum (Cefpirome + Sulbactam), Citrobacter to vancoplus (Ceftriaxone + vancomycin), Enterobacter to salbactomax (Ceftriaxone + salbactum). This betaLactam/betalactamase combination therapy may be tried against ESBL producing enterobacteriaceae where sole choice of therapy is with Imepenem.